BeyondSpring

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the PRC and U.S. geographical segments. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in New York, NY.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.

Gilead Acquired Forty Seven in March 2020 for $4.9 Billion Gilead Acquired Forty Seven in March 2020 for $4.9 Billion

BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr.

BeyondSpring's Plinabulin Offers Multiple Roadmaps (Via Multiple Geographies) To Becoming A Blockbuster

- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients -

BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.

Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ Progenitor Cells through a Mechanism of Action Independent from G-CSFs and CXCR4 Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ Progenitor Cells through a Mechanism of Action Independent from G-CSFs and CXCR4 

New Stem Cell-Based Application for BeyondSpring’s Plinabulin Presented at ISSCR Annual Meeting

BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

BeyondSpring (BYSI) Catches Eye: Stock Jumps 10.9%

The company announced the pricing of a public offering of common stock.

Why BeyondSpring Is Plunging Today

-Met Primary Endpoint of Rate of Severe (Grade 4) Neutropenia Prevention in First Chemotherapy Cycle (Cycle 1) (p

BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention

- PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN -

BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update

- Plinabulin in Combination with Neulasta Improves Dose and Regimen Compliance of TAC Chemotherapy Compared to Neulasta Alone -

BeyondSpring’s PROTECTIVE-2 (Study 106) Phase 2 Trial for Chemotherapy-Induced Neutropenia Shows Positive Results in Chemotherapy Optimization with Potentially Better Clinical Outcomes

- DSMB Reviewed Over 500 Patients’ Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC -

BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification

NEW YORK, May  13, 2020  (GLOBE NEWSWIRE) --  BeyondSpring  (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent, U.S. 10,596,169, for methods of treating severe chemotherapy-induced neutropenia (CIN) from Taxane in cancer patients by administering its lead asset Plinabulin, with protection through 2033.

BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2019 Results - Earnings Call Transcript

NEW YORK, April  30, 2020  (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the U.S. Securities and Exchange Commission (“SEC”) on April 30, 2020. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section.

BeyondSpring Files 2019 Annual Report on Form 20-F

The Potential for Superior and Rapid Onset Protection from Infection with Plinabulin-G-CSF Combination Marks First Significant Enhancement in Preventing Neutropenia in 30 Years The Potential for Superior and Rapid Onset Protection from Infection with Plinabulin-G-CSF Combination Marks First Significant Enhancement in Preventing Neutropenia in 30 Years

CORRECTION – FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study

-  Potential to be First Superior Therapy to Standard of Care for Chemotherapy-Induced Neutropenia in 30 Years -

BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia

NEW YORK, March  11, 2020  (GLOBE NEWSWIRE) --  BeyondSpring Inc.  (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the submission of a provisional U.S. patent application for its pipeline asset BPI-002, for methods of treating viral infections, including COVID-19, when administered alone or in combination with a vaccine. BPI-002 is a novel orally administered small molecule agent that is a potent T-cell co-stimulator.

BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19

Earthstone Energy

Evofem Biosciences Inc

Misonix

Playa Hotels & Resorts

Sequans Communications

No matter which strategy is employed or what types of stocks are sought after, investors want to see returns. 
The post 7 ‘Strong Buy’ Stocks With Over 50% Upside Potential appeared first on InvestorPlace.

7 ‘Strong Buy’ Stocks With Over 50% Upside Potential

Presentation at the 2020 ASCO-SITC Provides Strong Validation for Plinabulin as a Potent activator of the Innate Immune System Presentation at the 2020 ASCO-SITC Provides Strong Validation for Plinabulin as a Potent activator of the Innate Immune System

BeyondSpring’s Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients

NEW YORK, Jan.  23, 2020  (GLOBE NEWSWIRE) --  BeyondSpring Inc.  (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the appointments of Drs. Daniel Zabrowski and Ramon Mohanlal to the Company’s Board of Directors.

BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors

Plinabulin Protects Bone Marrow from Chemotherapy-Induced Deficiencies with a Differentiated Yet Complimentary Mechanism to G-CSF for CIN Prevention Plinabulin Protects Bone Marrow from Chemotherapy-Induced Deficiencies with a Differentiated Yet Complimentary Mechanism to G-CSF for CIN Prevention

BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q3 2019 Results - Earnings Call Transcript

Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negative Trial Outcome, and was Avoided in DUBLIN-3 Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negative Trial Outcome, and was Avoided in DUBLIN-3

BeyondSpring’s Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019

NEW YORK, Nov.  06, 2019  (GLOBE NEWSWIRE) --  BeyondSpring Inc.  (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has appointed Gregg Russo as Senior Vice President, Human Resources, effectively immediately.

BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources

The stock is down due to the recent share offering done at a 20% discount to market price.

BeyondSpring: The Drop From The Capital Raise Offers A Good Entry Point

NEW YORK, Oct.  25, 2019  (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 1,851,852 ordinary shares at a public offering price of $13.50 per share. The offering was led by Decheng Capital. The gross proceeds from the public offering are expected to be $25.0 million, before deducting underwriting discounts and commissions and other offering expenses. The underwriters have a 30-day option to purchase from the Company up to an additional 277,777 ordinary shares at the public offering price. The Company intends to use the net proceeds of this offering to support continued clinical and pre-clinical development and for general corporate purposes. The offering is expected to close on October 29, 2019, subject to satisfaction of customary closing conditions.

News for BeyondSpring Stock (BYSI)